• hoof_banier_01

Onsuiwerhede van aminosuur wat gebruik word vir die sintese van proteïene

Kort beskrywing:

NO

Produkte

CAS-nommer

1

Fmoc-D-Ala-D-Ala-OH

NA

2

Fmoc-β-Ala-D-Ala-OH

NA

3

Fmoc-Arg(pbf)-Arg(pbf)-OH

NA


Produkbesonderhede

Produk-etikette

Produkbesonderhede

NO

Produkte

CAS-nommer

Sleutelkwaliteitsaanwyser

Suiwerheid

Maks.

onreinheid

Totale oplosmiddelresidu

Vog

1

Fmoc-β-Ala-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

2

Fmoc-D-Ala-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

3

Fmoc-β-Ala-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

4

Fmoc-Arg(pbf)-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

5

Fmoc-β-Ala-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

6

Fmoc-D-Arg(pbf)-D-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

7

Fmoc-β-Ala-D-Arg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

8

Fmoc-HomoArg(pbf)-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

9

Fmoc-β-Ala-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

10

Fmoc-Asn(Trt)-Asn(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

11

Fmoc-β-Ala-Asn(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

12

Fmoc-Asp(OtBu)-Asp(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

13

Fmoc-β-Ala-Asp(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

14

Fmoc-Cys(Trt)-Cys(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

15

Fmoc-β-Ala-Cys(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

16

Fmoc-Cys(Acm)-Cys(Acm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

17

Fmoc-β-Ala-Cys(Acm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

18

Fmoc-Gln(Trt)-Gln(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

19

Fmoc-β-Ala-Gln(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

20

Fmoc-Glu(OtBu)-Glu(OtBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

21

Fmoc-β-Ala-Glu(OtBu)-OH.H2O

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

22

Fmoc-β-Ala-Gly-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

23

Fmoc-His(Trt)-His(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

24

Fmoc-β-Ala-His(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

25

Fmoc-Ile-Ile-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

26

Fmoc-β-Ala-Ile-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

27

Fmoc-Leu-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

28

Fmoc-β-Ala-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

29

Fmoc-D-Leu-D-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

30

Fmoc-β-Ala-D-Leu-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

31

Fmoc-Lys(Boc)-Lys(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

32

Fmoc-β-Ala-Lys(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

33

Fmoc-Lys(Alloc)-Lys(Alloc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

34

Fmoc-β-Ala-Lys(Alloc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

35

Fmoc-Met-Met-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

36

Fmoc-β-Ala-Met-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

37

Fmoc-Orn(Boc)-Orn(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

38

Fmoc-β-Ala-Orn(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

39

Fmoc-Phe-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

40

Fmoc-β-Ala-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

41

Fmoc-D-Phe-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

42

Fmoc-β-Ala-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

43

Fmoc-Pro-Pro-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

44

Fmoc-β-Ala-Pro-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

45

Fmoc-Ser(tBu)-Ser(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

46

Fmoc-β-Ala-Ser(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

47

Fmoc-Ser(Trt)-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

48

Fmoc-β-Ala-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

49

Fmoc-Thr(tBu)-Thr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

50

Fmoc-β-Ala-Thr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

51

Fmoc-Trp(Boc)-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

52

Fmoc-β-Ala-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

53

Fmoc-D-Trp(Boc)-D-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

54

Fmoc-β-Ala-D-Trp(Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

55

Fmoc-Tyr(tBu)-Tyr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

56

Fmoc-β-Ala-Tyr(tBu)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

57

Fmoc-D-Tyr(Et)-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

58

Fmoc-β-Ala-D-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

59

Fmoc-Tyr(Me)-Tyr(Me)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

60

Fmoc-β-Ala-Tyr(Me)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

61

Fmoc-Val-Val-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

62

Fmoc-β-Ala-Val-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

63

Fmoc-D-Cit-D-Cit-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

64

Fmoc-β-Ala-D-Cit-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

65

Fmoc-β-Ala-Dab-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

66

Fmoc-(3-(2-naftiel)-D-Ala)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

67

Fmoc-β-Ala-3-(2-naftiel)-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

68

Fmoc-(3-(3-piridiniel)-D-Ala)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

69

Fmoc-β-Ala-3-(3-piridiniel)-D-Ala-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

70

Fmoc-(4-chloro-D-Phe)2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

71

Fmoc-β-Ala-4-chloro-D-Phe-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

72

Fmoc-(D-4Aph(tBuCbm))2-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

73

Fmoc-β-Ala-D-4Aph(tBuCbm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

74

Fmoc-Aph(L-Hor)-Aph(L-Hor)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

75

Fmoc-β-Ala-Aph(L-Hor)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

76

Fmoc-Lys(iPr,Boc)-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

77

Fmoc-β-Ala-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

78

Fmoc-β-Ala-AEEA-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

79

Fmoc-Aib-Aib-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

80

Fmoc-β-Ala-Aib-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

81

Fmoc-Arg-OH

91000-69-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

82

H-Arg(pbf)-OH

200115-86-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

83

Fmoc-D-Arg-OH

130752-32-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

84

HD-Arg(pbf)-OH

200116-81-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

85

Fmoc-HomoArg-OH.HCl

208174-14-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

86

H-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

87

Fmoc-D-HomoArg-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

88

HD-HomoArg(pbf)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

89

Fmoc-Asn-OH

71989-16-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

90

H-Asn(Trt)-OH

132388-58-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

91

Fmoc-Asp-OH

119062-05-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

92

H-Asp(OtBu)-OH

3057-74-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

93

Fmoc-Cys-OH

135248-89-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

94

H-Cys(Trt)-OH

2799/7/7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

95

H-Cys(Acm)-OH.HCl

28798-28-9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

96

Fmoc-Gln-OH

71989-20-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

97

H-Gln(Trt)-OH

102747-84-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

98

Fmoc-Glu-OH

121343-82-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

99

H-Glu(OtBu)-OH.H2O

2419-56-9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

100

Fmoc-His-OH

116611-64-4

≥98.0%

≤1.0%

≤8.0%

≤2.0%

101

H-His(Trt)-OH

35146-32-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

102

Boc-His-OH

17791-52-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

103

Fmoc-Lys-OH

105047-45-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

104

H-Lys(Boc)-OH

2418-95-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

105

H-Lys(Allok)-OH

6298/3/9

≥98.0%

≤1.0%

≤8.0%

≤2.0%

106

Fmoc-Orn-OH.HCl

201046-57-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

107

H-Orn(Boc)-OH

13650-49-2

≥98.0%

≤1.0%

≤8.0%

≤2.0%

108

Fmoc-Ser-OH

73724-45-5

≥98.0%

≤1.0%

≤8.0%

≤2.0%

109

H-Ser(tBu)-OH

18822-58-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

110

H-Ser(Trt)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

111

Fmoc-Thr-OH.H2O

73731-37-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

112

H-Thr(tBu)-OH

4378-13-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

113

Fmoc-Trp-OH

35737-15-6

≥98.0%

≤1.0%

≤8.0%

≤2.0%

114

H-Trp(Boc)-OH

146645-63-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

115

Fmoc-D-Trp-OH

86123-11-7

≥98.0%

≤1.0%

≤8.0%

≤2.0%

116

HD-Trp(Boc)-OH

201290-11-1

≥98.0%

≤1.0%

≤8.0%

≤2.0%

117

Fmoc-Tyr-OH

92954-90-0

≥98.0%

≤1.0%

≤8.0%

≤2.0%

118

H-Tyr(tBu)-OH

18822-59-8

≥98.0%

≤1.0%

≤8.0%

≤2.0%

119

Fmoc-D-Tyr-OH

112883-29-1

≥98.0%

≤1.0%

≤8.0%

≤2.0%

120

HD-Tyr(Et)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

121

H-Tyr(Me)-OH.HCl

67423-44-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

122

Fmoc-D-4Aph(Cbm)-OH

324017-22-3

≥98.0%

≤1.0%

≤8.0%

≤2.0%

123

HD-4Aph(tBuCbm)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

124

Fmoc-Lys(iPr)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

125

H-Lys(iPr,Boc)-OH

NA

≥98.0%

≤1.0%

≤8.0%

≤2.0%

Oor

Vergoeding

Gentolex bied produkte van hoë gehalte. Indien die kliënt binne die vereiste tydsbestek met voldoende bewyse die produkkwaliteit verhoog, sal ons die nodige ontleding en evaluering verskaf om die vergoedingsprosedures te aktiveer.

Produksie

Die kapasiteit van farmaseutiese produkte het tongraad bereik, die kapasiteit van chemiese produkte bereik 100 ton+ graad, die vermoëns is goed toegerus om kliënte wêreldwyd te bedien.

Navorsing en Ontwikkeling

Elke jaar stel die O&O-span 'n plan op om verskillende nuwe produkte te ontwikkel. Wanneer teikens gestel word, sal elke lid in die span moet voortgaan met KPI-verantwoordelikheid en met 'n aansporingsbeleid.


  • Vorige:
  • Volgende:

  • Skryf jou boodskap hier en stuur dit vir ons